Following the halt of cutaneous lupus erythematosus development, a possibility of halting Sjögren's syndrome after completing phase 2 was mentioned; the pipeline value damage from indication discontinuations is judged limited.

A statement by 현대차증권 제약/바이오/의료기기 김현석. Statements are as reported by the cited publishers — not verified by DecisionGateway.

피부홍반성루푸스 개발 중단에 이어 쇼그렌증후군도 2상 마무리 이후 중단 가능성 언급